# Evaluating the Effects of Tasimelteon Vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD) and the CRY1Δ11 Variant

> **NCT06701396** · PHASE3 · RECRUITING · sponsor: **Vanda Pharmaceuticals** · enrollment: 60 (estimated)

## Conditions studied

- Sleep Wake Disorders
- Sleep Disorders, Circadian Rhythm
- Chronobiology Disorders
- Gene Mutations and Other Alterations Nec

## Interventions

- **DRUG:** Tasimelteon
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06701396
- **Lead sponsor:** Vanda Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-08
- **Primary completion:** 2025-06-30
- **Final completion:** 2025-06-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2024-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06701396

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06701396, "Evaluating the Effects of Tasimelteon Vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD) and the CRY1Δ11 Variant". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06701396. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*